PSNL logo

PSNL Personalis, Inc.

NASDAQ Global Market · Medical - Diagnostics & Research · Healthcare

$15.82
-0.08 (-0.50%)

Personalis, Inc. operates globally as a specialized cancer genomics firm. The company delivers advanced sequencing and data analysis capabilities, primarily supporting the development of novel cancer treatments and facilitating extensive genetic research initiatives. Central to their offerings is the NeXT Platform, which enables detailed data analysis of tumors and their surrounding immune microen…

Market Cap: $1.69Bwww.personalis.com

Price

No data yet.

Social Signal Score

51
5d
51
3 mentions
—
30d
50
3 mentions
—
60d
52
4 mentions
—
90d
52
4 mentions
—
news: 4

Analyst Ratings

12 analysts
Buyconsensus
Strong Buy 0Buy 8Hold 4Sell 0Strong Sell 0
Avg price target$14.95-5.5%
Low $9Median $16.25High $17
Current Consensus

Revenue

$22.36M+436.91%
$4.16M$11.35M$18.53M$25.71M
Mar 2018Jun 2026

Analyst Estimates

FY2025
$-0.94
$-1.00–$-0.89
4 analysts
FY2026
$-1.09
$-1.15–$-1.03
3 analysts
FY2027
$-0.94
$-1.00–$-0.88
5 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Christopher Hall
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Employees
260
Beta
2.32
Country
US
Piotroski score
1 / 9 (Weak)
Altman Z-score
9.98
www.personalis.com